Rituximab treatment in non-lupus full-house nephropathy: A case report.

IF 0.6 Q3 MEDICINE, GENERAL & INTERNAL

SAGE Open Medical Case Reports Pub Date : 2025-05-13 eCollection Date: 2025-01-01 DOI:10.1177/2050313X251333979

Caroline Gee, Dao Le, Matthew D Nguyen, Anthony Sisk, Ramy Hanna

{"title":"Rituximab treatment in non-lupus full-house nephropathy: A case report.","authors":"Caroline Gee, Dao Le, Matthew D Nguyen, Anthony Sisk, Ramy Hanna","doi":"10.1177/2050313X251333979","DOIUrl":null,"url":null,"abstract":"<p><p>Non-lupus full-house nephropathy describes a pattern of \"full-house\" immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic lupus erythematosus. Current treatment options are lacking, with mixed results in the literature for varied immunosuppressive regimens. Rituximab, a selective anti-CD20 B-cell monoclonal antibody, has shown success in immune-complex mediated glomerular diseases but has not been commonly used or studied in non-lupus full-house nephropathy. Here, we present a case of non-lupus full-house nephropathy that was refractory to first-line immunosuppressants, in which two rounds of rituximab treatment achieved a positive response. This case emphasizes the need for systemic analysis of rituximab use in non-lupus full-house nephropathy, particularly given its mixed etiologies and presentations.</p>","PeriodicalId":21418,"journal":{"name":"SAGE Open Medical Case Reports","volume":"13 ","pages":"2050313X251333979"},"PeriodicalIF":0.6000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075972/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"SAGE Open Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2050313X251333979","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Non-lupus full-house nephropathy describes a pattern of "full-house" immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic lupus erythematosus. Current treatment options are lacking, with mixed results in the literature for varied immunosuppressive regimens. Rituximab, a selective anti-CD20 B-cell monoclonal antibody, has shown success in immune-complex mediated glomerular diseases but has not been commonly used or studied in non-lupus full-house nephropathy. Here, we present a case of non-lupus full-house nephropathy that was refractory to first-line immunosuppressants, in which two rounds of rituximab treatment achieved a positive response. This case emphasizes the need for systemic analysis of rituximab use in non-lupus full-house nephropathy, particularly given its mixed etiologies and presentations.

查看原文本刊更多论文

利妥昔单抗治疗非狼疮性全屋肾病1例。

在缺乏系统性红斑狼疮的临床或血清学标记物的情况下，非狼疮性满屋肾病描述了肾活检的“满屋”免疫荧光模式。它是一种罕见的疾病，病因广泛，包括特发性、继发性或系统性红斑狼疮的前驱症状。目前缺乏治疗方案，文献中各种免疫抑制方案的结果不一。利妥昔单抗（Rituximab）是一种选择性抗cd20 b细胞单克隆抗体，在免疫复合物介导的肾小球疾病中显示出成功，但在非狼疮性满室肾病中尚未得到普遍应用或研究。在这里，我们提出了一个非狼疮性全屋肾病的情况下，是难治性一线免疫抑制剂，其中两轮利妥昔单抗治疗取得了积极的反应。本病例强调了系统分析利妥昔单抗在非狼疮性全室肾病中的应用的必要性，特别是考虑到其复杂的病因和表现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

SAGE Open Medical Case Reports MEDICINE, GENERAL & INTERNAL-

CiteScore

0.60

自引率

0.00%

发文量

320

审稿时长

8 weeks

期刊介绍： SAGE Open Medical Case Reports (indexed in PubMed Central) is a peer reviewed, open access journal. It aims to provide a publication home for short case reports and case series, which often do not find a place in traditional primary research journals, but provide key insights into real medical cases that are essential for physicians, and may ultimately help to improve patient outcomes. SAGE Open Medical Case Reports does not limit content due to page budgets or thematic significance. Papers are subject to rigorous peer review and are selected on the basis of whether the research is sound and deserves publication. By virtue of not restricting papers to a narrow discipline, SAGE Open Medical Case Reports facilitates the discovery of the connections between papers, whether within or between disciplines. Case reports can span the full spectrum of medicine across the health sciences in the broadest sense, including: Allergy/Immunology Anaesthesia/Pain Cardiovascular Critical Care/ Emergency Medicine Dentistry Dermatology Diabetes/Endocrinology Epidemiology/Public Health Gastroenterology/Hepatology Geriatrics/Gerontology Haematology Infectious Diseases Mental Health/Psychiatry Nephrology Neurology Nursing Obstetrics/Gynaecology Oncology Ophthalmology Orthopaedics/Rehabilitation/Occupational Therapy Otolaryngology Palliative Medicine Pathology Pharmacoeconomics/health economics Pharmacoepidemiology/Drug safety Psychopharmacology Radiology Respiratory Medicine Rheumatology/ Clinical Immunology Sports Medicine Surgery Toxicology Urology Women''s Health.